Abstract
Introduction Telomere length (TL) is generally regarded as a biomarker of aging. TL, which is influenced by sociodemographic factors, has been shown to be inversely associated with morbidity. However, most studies were examined in the youngest old and whether the findings can be extended to the oldest old is less clear. This study examined TL and its associated factors in Chinese oldest old in Hong Kong.
Methods Follow-up data collected after 14 years from the baseline of the Mr. and Ms. Osteoporosis cohort were analyzed. A structured interview on sociodemographic factors and physical measurement was conducted. Frailty and sarcopenia status were respectively determined by Fried’s criteria and Asian Working Group for Sarcopenia definition. TL was measured by a molecular inversion probe - quantitative PCR (MIP-qPCR) assay and expressed as telomere / a single copy reference gene (T/S) ratio. Adjusted binary logistic regressions were used to examine the associations between TL and the presence of multimorbidity, age-related diseases, frailty and sarcopenia.
Results Among 555 participants (mean age 83.6±3.8 years, 41.3% women), the mean T/S ratio was 1.01±0.20. Males had lower T/S ratio (0.97±0.20) compared with females (1.07±0.18) (p<0.001). A lower education level was related to a longer TL (p=0.016). Being a current smoker was related to a shorter TL (p=0.007). TL was not significantly different across categories of age, subjective socioeconomic status, drinking status, physical activity level and body mass index (p>0.05). There were no associations between TL and the presence of multimorbidity, diabetes, stroke, cardiovascular diseases, cognitive impairment, frailty and sarcopenia.
Conclusion Among Chinese oldest old, males had shorter TL compared with females. TL was not associated with age-related diseases, frailty and sarcopenia in this age group. TL may not be a biological marker of aging among the oldest old.
Competing Interest Statement
The method of telomere length measurement is pending patent proceedings.
Funding Statement
This work was supported by the Hong Kong Jockey Club Charities Trust. We thank the generous donation of Ms. Therese Pei Fong Chow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clinical Research Ethics Committee of the Chinese University of Hong Kong gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
